Daily Clinical Briefing · Educational reading for healthcare professionals
Late alteplase improves one recovery measure but raises bleeding risk and leaves important timing questions unresolved.
When discussing HOPE, use comparable absolute figures: approximately 14 more favourable functional outcomes and 3.3 more symptomatic intracranial haemorrhages per 100 patients receiving alteplase.
Acute ischaemic stroke does not progress at the same speed in every patient. Collateral circulation and other factors influence how quickly brain tissue becomes irreversibly injured. This raises an important clinical question: could some patients still benefit from alteplase many hours after their stroke begins?
The HOPE trial examines alteplase between 4.5 and 24 hours in a carefully selected population. Patients needed CT perfusion evidence of salvageable brain tissue, minimal pre-stroke disability (modified Rankin Scale 0–1), an NIH Stroke Scale score of 4–26 and no initial plan for thrombectomy. Of 3,885 patients screened, only 372 were randomised. That narrow eligibility matters when deciding whether the findings apply to a patient in front of us.
At 90 days, 40% of patients receiving alteplase achieved a modified Rankin Scale score of 0–1, compared with 26% of controls. That represents approximately 14 additional patients per 100 reaching little or no disability.
But there is a price. Symptomatic intracranial haemorrhage occurred in 3.8% of patients receiving alteplase compared with 0.5% of controls, an absolute increase of approximately 3.3 per 100. Observed mortality was identical at 10.8% in both groups. The potential functional benefit needs to be considered alongside that additional bleeding risk.
What counts as a good recovery?
HOPE defines its primary favourable outcome as a modified Rankin Scale score of 0 or 1. Everyone scoring between 2 and 6 falls into the unfavourable group.
That simplifies analysis but discards important differences in disability. A patient improving from a score of 4 to 3 may experience a meaningful improvement in daily life, yet remains an unfavourable outcome in the primary analysis. Different approaches to weighting disability can produce different interpretations of the treatment effect.
How much of the 24-hour window is supported?
Perhaps the most important limitation is the distribution of patients within the trial.
Only 51 participants had a known stroke onset between nine and 24 hours. The confidence interval for this subgroup was wide and crossed the null. Most participants were treated between 4.5 and nine hours or had wake-up or unwitnessed strokes.
The positive overall result therefore cannot establish routine benefit for patients presenting more than nine hours after a known onset.
HOPE also used an open-label design. Although outcome assessors were masked, clinicians and patients knew the allocated treatment, creating potential performance bias.
For clinical practice, this means doing more than checking the clock or identifying salvageable tissue. We need to establish pre-stroke function, stroke severity, perfusion findings and thrombectomy plans before deciding how closely a patient resembles those studied.
When treatment is being considered, explain the absolute potential benefit, the additional risk of symptomatic bleeding and the uncertainty around later known-onset strokes. A 24-hour eligibility window should not become an automatic 24-hour treatment rule.
In selected late-window ischaemic stroke, HOPE finds more patients with little or no disability after alteplase, alongside more symptomatic intracranial haemorrhage. Limited evidence for known-onset stroke beyond nine hours and the definition of functional recovery complicate interpretation.
Crohn's disease may cause skip lesions and transmural complications, while ulcerative colitis usually produces continuous mucosal inflammation from the rectum. Their complex immune pathways explain why blocking a pro-inflammatory cytokine does not always improve disease.
Reducing low-value care requires explicit teaching, recognition of appropriate restraint and interventions matched to local causes of overuse. Ward-based examples include proton pump inhibitor review, urinary catheter removal and measuring patient outcomes alongside resource use.
For suspected acute stroke, establish and document last-known-well and symptom-recognition times, and check blood glucose.
Before applying late-window alteplase evidence, confirm pre-stroke disability, NIH Stroke Scale score, CT perfusion findings and thrombectomy plans.
Discuss functional benefit and symptomatic intracranial bleeding using absolute risks rather than relying on the headline treatment window.
An adult with acute ischaemic stroke has a known symptom onset 12 hours earlier. CT perfusion demonstrates salvageable tissue, and no thrombectomy is planned. What limitation of the HOPE evidence is most relevant before considering late-window alteplase?
Only 51 participants had a known onset between nine and 24 hours, and the subgroup confidence interval was wide and crossed the null. The overall positive result does not establish benefit for routine alteplase in this later known-onset population.
A patient has recurrent non-bloody diarrhoea, terminal ileal inflammation, skip lesions and a fistula. Which inflammatory characteristic explains the penetrating complication?
Transmural inflammation in Crohn's disease extends through the bowel wall and can produce fistulas and abscesses. Associated fibrosis can also cause strictures and intestinal obstruction.
A medical ward introduces daily urinary catheter review and a nurse-led removal protocol. Catheter days subsequently fall. Which additional outcome would best establish whether the intervention benefits patients?
The rate of catheter-associated urinary tract infections. Measuring infection rates alongside catheter days allows the team to assess patient benefit rather than simply a reduction in device use.
Daily Clinical Briefings are prepared using ChatGPT Pro from the show notes and educational output for that day’s episodes. Iain Beardsell then checks the briefing for accuracy.
This describes the current briefing process. Item-specific review dates are shown only where documented. The original podcasts remain the sources; MedPod’s briefing is additional educational material.
Read about MedPod’s editorial approach
Report an error or source concern — please include the article title and link, without patient-identifying information.
.svg)